Key result
Current methods for recombinant AAV-2 vector production and purification are being advanced to develop new scalable procedures that meet GMP requirements for clinical trials.
This review highlights advancements in scalable production and purification methods for rAAV-2 vectors to meet GMP requirements for clinical trials.
Answers are grounded in this paper and cite their sources.
Advances scalable GMP-compliant AAV production; leaves open clinical translation and efficacy in cardiovascular gene therapy.
Numerous in vivo studies have demonstrated that recombinant AAV-2 vectors (rAAV-2) can efficiently transduce many tissues and lead to stable gene expression 12. These encouraging results have led to a rapid development of clinical trials involving the use of rAAV-2 vectors 3. However, the obtainment of large-scale rAAV-2 vector stocks for clinical assay is still hampered by the conventional production and purification methods that are not efficient and difficult to scale up. This review will describe the current methods available for rAAV-2 vector production and purification and show the advancements achieved, in particular in our group, to develop new scalable procedures, suiting GMP requirements.
No takes yet. Share an insight, caveat, or question.
Blouin et al. (2004) reported a review. rAAV-2 vector production and purification methods was evaluated. Current methods for recombinant AAV-2 vector production and purification are being advanced to develop new scalable procedures that meet GMP requirements for clinical trials.
Synapse has enriched 10 related papers. Consider them for comparative context: